|Day's range||21.08 - 21.25|
|52-week range||18.16 - 22.98|
|PE ratio (TTM)||47.86|
|Dividend & yield||0.95 (5.02%)|
|1y target est||N/A|
Glaxo shares dipped near a two-week low after Gilead's HIV drug combination proved to be non-inferior in a late-stage trial.
The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX
Three decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel experimental vaccine. The Achilles heel for us is drug resistance because the virus is incredibly quick to mutate," Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre in South Africa, said. The race for better and more convenient medicines has made HIV a rich battleground for drug companies such as Gilead Sciences and GlaxoSmithKline, which generate billions of dollars from modern therapies.